Jemila Caplan Kester

Dr. Jemila Caplan Kester

Department of Biomedicine, Auckland University of Technology, Auckland, New Zealand
orcid
Open for collaboration

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Med
Verified
Journal Article
Open access
JZJianbo Zhang
Jianbo Zhang
YHYu-Ja Huang
Yu-Ja Huang
JYJun Young Yoon
Jun Young Yoon
JKJohn Kemmitt
John Kemmitt
CWCharles Wright
Charles Wright
LGLinda G. Griffith
Linda G. Griffith
The gut microbiome plays an important role in human health and disease. Gnotobiotic animal and in vitro cell-based models provide some informative insights into mechanistic crosstalk. However, there is no existing system for a long-term co-culture of a human colonic mucosal barrier with super oxygen-sensitive commensal microbes, hindering the study of human-microbe interactions in a controlled manner. Here, we investigated the effects of an abundant super oxygen-sensitive commensal anaerobe, Faecalibacterium prausnitzii, on a primary human mucosal barrier using a Gut-MIcrobiome (GuMI) physiome platform that we designed and fabricated. Long-term continuous co-culture of F. prausnitzii for two days with colon epithelia, enabled by continuous flow of completely anoxic apical media and aerobic basal media, resulted in a strictly anaerobic apical environment fostering growth of and butyrate production by F. prausnitzii, while maintaining a stable colon epithelial barrier. We identified elevated differentiation and hypoxia-responsive genes and pathways in the platform compared with conventional aerobic static culture of the colon epithelia, attributable to a combination of anaerobic environment and continuous medium replenishment. Furthermore, we demonstrated anti-inflammatory effects of F. prausnitzii through HDAC and the TLR-NFKB axis. Finally, we identified that butyrate largely contributes to the anti-inflammatory effects by downregulating TLR3 and TLR4. Our results are consistent with some clinical observations regarding F. prausnitzii, thus motivating further studies employing this platform with more complex engineered colon tissues for understanding the interaction between the human colonic mucosal barrier and microbiota, pathogens, or engineered bacteria.

1 December 2021 in Cell Reports
Verified
Journal Article
Open access
JZJunhao Zhu
Junhao Zhu
IWIan D. Wolf
Ian D. Wolf
CDCharles L. Dulberger
Charles L. Dulberger
HWHarim I. Won
Harim I. Won
Jemila Caplan KesterJemila Caplan Kester
Jemila Caplan Kester
EREric J. Rubin
Eric J. Rubin
Although prokaryotic organisms lack traditional organelles, they must still organize cellular structures in space and time, challenges that different species solve differently. To systematically define the subcellular architecture of mycobacteria, we perform high-throughput imaging of a library of fluorescently tagged proteins expressed in Mycobacterium smegmatis and develop a customized computational pipeline, MOMIA and GEMATRIA, to analyze these data. Our results establish a spatial organization network of over 700 conserved mycobacterial proteins and reveal a coherent localization pattern for many proteins of known function, including those in translation, energy metabolism, cell growth and division, as well as proteins of unknown function. Furthermore, our pipeline exploits morphologic proxies to enable a pseudo-temporal approximation of protein localization and identifies previously uncharacterized cell-cycle-dependent dynamics of essential mycobacterial proteins. Collectively, these data provide a systems perspective on the subcellular organization of mycobacteria and provide tools for the analysis of bacteria with non-standard growth characteristics.

24 March 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
Jemila Caplan KesterJemila Caplan Kester
Jemila Caplan Kester
DBDouglas K. Brubaker
Douglas K. Brubaker
JVJason Velazquez
Jason Velazquez
CWCharles Wright
Charles Wright
DLDouglas A. Lauffenburger
Douglas A. Lauffenburger
LGLinda G. Griffith
Linda G. Griffith
A clinically relevant risk factor for Clostridioides difficile -associated disease (CDAD) is recent antibiotic treatment. Although broad-spectrum antibiotics have been shown to disrupt the structure of the gut microbiota, some antibiotics appear to increase CDAD risk without being highly active against intestinal anaerobes, suggesting direct nonantimicrobial effects. We examined cell biological effects of antibiotic exposure that may be involved in bacterial pathogenesis using an in vitro germfree human colon epithelial culture model.

28 June 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
Fathima Zahraa OzeerFathima Zahraa Ozeer
Fathima Zahraa Ozeer
Jemila Caplan KesterJemila Caplan Kester
Jemila Caplan Kester
The tumor microbiome has been implicated in pancreatic ductal adenocarcinoma (PDAC)’s poor response to treatment, demanding new methods for understanding host-microbe interactions in therapy. Traditional 2D systems, while widely used, fail to adequately recapitulate human PDAC due to insufficient representation of structural, immunological and stromal components. Differences in cancer-specific microbiomes, microbe-immune interactions, and the unique physiological and immunosuppressive features unique to PDAC have hindered the clinical translation of immune therapies. Reproducible 3D culture systems that integrate the human microbe-tumor-immune (MTI) axis represent a promising avenue for treatment research, yet they remain underexplored in PDAC. In this narrative review, we discuss the key microbial determinants of therapy resistance, explore the current 3D multicellular modeling approaches in other cancer types, and provide a path forward for similar integrative translational models in PDAC.

3 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
EHEvelyn Yu-Wen Huang
Evelyn Yu-Wen Huang
KJKatherine Jeppe
Katherine Jeppe
JZJingsong Zhou
Jingsong Zhou
CBChristopher Barlow
Christopher Barlow
Jemila Caplan KesterJemila Caplan Kester
Jemila Caplan Kester
Ivanhoe LeungIvanhoe Leung
Ivanhoe Leung
Mycobacterium tuberculosis persists within the host by exploiting metabolic flexibility underpinned by the tricarboxylic acid (TCA) cycle-glyoxylate shunt junction, where isocitrate dehydrogenase (ICD) and isocitrate lyase (ICL) compete to direct carbon flux between energy production and carbon conservation. Yet, how nutrient availability regulates flux partitioning at this junction is unknown. We show that among the four gatekeeping isoforms of isocitrate lyase (ICL1/2) and isocitrate dehydrogenase (ICD1/2), only icl1 transcription substantially responds to carbon substrate switching. Systematic metabolite screening revealed that pyruvate, oxaloacetate, and glyoxylate are novel allosteric activators of ICD2, while concurrently inhibiting ICL1/2 at their physiological concentrations. To resolve how these regulatory layers integrate, we developed an experimental 1H NMR-based flux assay that combines recombinant enzymes with metabolomics-informed metabolite conditions to quantify flux partitioning under defined states. This systems-level framework reveals that flux partitioning emerges from coordinated balancing of enzyme abundance and protein-metabolite effector combinations that shift in a time-dependent, nutrient-responsive manner. This dynamic, multi-layered regulatory framework, analogous to a 'mixer-tap' mechanism, offers new strategies for therapeutic disruption of M. tuberculosis metabolism.

7 August 2019 in bioRxiv
Verified
Preprint
Open access
Jemila Caplan KesterJemila Caplan Kester
Jemila Caplan Kester
DBDouglas K. Brubaker
Douglas K. Brubaker
JVJason Velazquez
Jason Velazquez
CWCharles Wright
Charles Wright
DLDouglas A. Lauffenburger
Douglas A. Lauffenburger
LGLinda G. Griffith
Linda G. Griffith
The most clinically relevant risk factor for Clostridioides difficile -associated disease (CDAD) is recent antibiotic treatment. Though most broad-spectrum antibiotics significantly disrupt the structure of the gut microbiota, only particular ones increase CDAD risk, suggesting additional factors might increase the risk from certain antibiotics. Here we show that commensal-independent effects of antibiotics collectively prime an in vitro germ-free human gut for CDAD. We found a marked loss of mucosal barrier and immune function with CDAD-associated antibiotic pretreatment distinct from pretreatment with an antibiotic unassociated with CDAD, which did not reduce innate immune or mucosal barrier functions. Importantly, pretreatment with CDAD-associated antibiotics sensitized mucosal barriers to C. difficile toxin activity in primary cell-derived enteroid monolayers. These data implicate commensal-independent host changes in the increased risk of CDAD with specific antibiotics. Our findings are contrary to the previously held belief that antibiotics allow for CDAD solely through disruption of the microbiome. We anticipate this work to suggest potential avenues of research for host-directed treatment and preventive therapies for CDAD, and to impact human tissue culturing protocols.